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A b s t r A c t
We present a case of staged multivessel percutaneous coronary intervention (PCI) 
with drug-eluting-stents (DES) in a diabetic patient with three-vessel coronary heart 
disease (CHD), dialysis-dependent chronic renal failure and impaired left ventricular 
(LV) systolic function. The optimal method of coronary revascularization in dialysis 
patients is controversial. Surgical treatment (CABG) is a high-risk procedure. CABG 
in the pre- DES era was associated with a better long-term prognosis, but at the cost of 
higher in-hospital mortality. PCI using DES may be a feasible therapeutic alternative. 
The revascularization strategy is reviewed. 
c A s E  r E P O r t
A 50 year-old man admitted to our hospital with NYHA class III symptoms. He 
had no previous history of coronary heart disease (CHD) and had never experienced 
chest pain. He had a medical history of hypertension, insulin-dependent diabetes, 
and chronic renal failure that required hemodialysis the last two years. He had been 
a heavy smoker (40/daily) for 35 years. Blood pressure was 140/80 mmHg and heart 
rate was 2 beats/min. A twelve-lead ECG showed sinus rhythm, QS in V1-V3 and 
ST-T abnormalities in the inferior leads. Transthoracic echocardiography revealed 
hypokinesia of the anterior and inferior wall, akinesia of the apex and reduced systolic 
function with an estimated LV ejection fraction 35%. 
Cardiac catheterization showed 3-vessel disease with an 80% proximal and a 70% 
stenosis distal stenoses in the left anterior descending (LAD) coronary artery. A 70% 
stenosis was shown in the left circumflex (LCx). In the right coronary artery (RCA) 
four stenoses were revealed, 80% proximally, 80%, and 70% in the mid segment and 
an 80% stenosis involving the bifurcation distally.
The patient had been under medical therapy with perindopril 2 mg p.o bid, 
carvedilol 6.25 mg bid, aspirin 100 mg qd, and nitrates and had shown a significant 
clinical improvement.
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It was estimated, based on the EuroSCORE (European 
System for Cardiac Operative Risk Evaluation), that this pa-
tient had a high surgical risk (>6%), calculated at %. Based 
on this and considering also the preferences of the patient and 
his family, surgical treatment was not selected and a PCI with 
use of DES was scheduled. 
An Intek (paclitaxel-eluting) stent 3.5 x 18 mm was 
implanted in the proximal stenosis of the LAD and a second 
Intek stent 2.5 x 10 mm in the distal lesion. An Omega stent 
(also paclitaxel-eluting) 3 x 15 mm was implanted in the LCx. 
Three Intek stents (3x10 mm/3.5x18 mm/3.5x28 mm) were 
implanted in the RCA together with a Cypher stent (3.5x8 
mm).The patient was discharged with an optimal treatment 
for heart failure (HF), aspirin lifelong and clopidogrel for at 
least 12 months.
The patient was re-evaluated 3 months post PCI. 
Unfortunately he remained in NYHA III, with an unchanged 
LVEF 35%. However, it turned out that the patient had stopped 
taking his medications except for aspirin and clopidogrel. 
D I s c U s s I O N
Patients with chronic renal failure (CRF) constitute about 
10% of all patients with CHD undergoing PCI. These patients 
have a higher rate of in-hospital and long-term major adverse 
cardiac events. The leading cause of death in chronic renal 
dialysis patients is cardiovascular disease (1). As the number 
of advanced renal failure patients increases, we are encounter-
ing more patients with severe ischemic heart disease requir-
ing coronary intervention. The optimal method of coronary 
revascularization in dialysis patients is controversial.
Surgical treatment of these patients is a procedure of high 
risk as estimated with various well validated risk scoring sys-
tems. The EuroSCORE risk model on the basis of objective 
risk factors (patient-related, cardiac-related and operation-re-
lated factors) (Table 1) has been already extensively validated 
for the prediction of early mortality following open-heart sur-
gery. Although there is evidence highly suggestive that additive 
EuroSCORE performance generally over-estimates mortality 
at lower EuroSCOREs (EuroSCORE≤6) and under-estimates 
mortality at higher EuroSCOREs (EuroSCORE>13), it is 
used worldwide and several studies have documented its role 
as a relevant predictor of immediate and late outcome after 
on-pump CABG (2). Based on EuroSCORE estimated peri-
operative mortality risk is often unacceptably high in dialysis 
patients with multivessel CHD especially when LV systolic 
function is impaired or in an unstable/acute condition.
Several centers investigated the effectiveness and safety of 
different revascularization strategies in this challenging situa-
tion and their results were compared directly or indirectly. In 
the pre-DES era of PCI coronary stents improved prognosis 
in CRF patients, however long-term survival remained poor. 
CABG was associated with a better long-term prognosis but 
at the cost of higher in-hospital mortality. In a large retrospec-
tive study from 15 to 18, dialysis patients in the United 
States had better long-term survival after CABG surgery 
than after PCI. The 2-year survival was 56.4±1.4% for CABG 
patients, 48.2±1.5% for PTCA patients, and 48.4± 2.0% for 
stent patients (p<0.0001) (1). In the ARTS trial a multivessel 
PCI with bare-metal stent (BMS) implantation was compared 
with bypass surgery for multivessel CHD in patients with renal 
insufficiency. At 5 years, there was no significant difference 
between the two groups in terms of mortality (14.5% in the 
stent group vs. 12.3% in the CABG group, P: 0.81), or com-
bined endpoint of death, cerebrovascular accident (CVA), or 
myocardial infarction (MI) (30.4% in the stent group vs. 23.3% 
in the CABG group, p: 0.35). Among patients who survived 
without CVA or MI, 18.8% in the stent group underwent a 
second revascularization procedure when compared with 8.2% 
in the surgery group (p: 0.08). The event-free survival at 5 
years was 50.7% in the stent group and 68.5% in the surgery 
group (p: 0.04). (3) 
Although use of DES has revolutionized interventional 
cardiology minimizing in-stent restenosis the influence of 
their use on survival in patients with CRF is unknown. In 
a cohort of dialysis patients undergoing PCI, DES versus 
BMS implantation was associated with improved freedom 
from 1-year MACE (major cardiac events defined as death, 
myocardial infarction (MI) or any repeat revascularization 
procedure at 1-year follow up) [OR= 0.24, 5% CI 0.10-
0.60; p: 0.002)] (4) In ARTS II study a multivessel PCI was 
performed and the incidence of MACE, (death/MI/CVA, and 
revascularization at 1 year) was classified according to clinical 
presentation in the sirolimus eluting stents (SES) group and 
compared with the BMS or CABG groups of ARTS I. After 
adjustment for all confounders the MACE rate observed in the 
ARTS II remained consistently lower than that observed in the 
BMS group in stable (HR 0.45, 5% CI 0.16 - 0.58, p: 0.0004) 
or unstable patients (HR 0.43, 5% CI 0.18 - 0., p: 0.034), 
tAbLE 1. European System for Cardiac Operative Risk 
Evaluation /EuroSCORE
Patient-related factors cardiac-related factors 
Age (years)  Unstable angina   
Gender  LV function  
Chronic pulmonary disease  Recent MI     
Extracardiac arteriopathy  Pulmonary Hypertension 
Neurological dysfunction   Operation-related factors 
Previous Cardiac Surgery  Emergency 
Creatinine > 200 μmol/ L  Other than isolated CABG 
Active endocarditis  Surgery on thoracic aorta  
Critical preoperative Post infarct septal rupture 
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whereas it did not differ compared to the CABG group in 
stable (HR 2.38, 5% CI 0.33 - 16.7, p: 0.3) or unstable group 
(HR 0.33, 5% CI 0.03 - 3.22, p: 0.34) analyzed separately. The 
results from the use of SES in patients undergoing multivessel 
intervention are equivalent to the rate of major adverse events 
as compared with CABG treatment. (5)
PCI with DES implantation may be an effective rea-
sonable safe revascularization procedure in patients with 
dialysis-dependent chronic renal failure. On the other hand, 
when LVEF is reduced in patients in dialysis with multivessel 
CHD, diabetic or not and, various degrees of stunning and 
hibernating myocardium (HM) and remodelling of the heart 
may exist and more complex diagnostic and therapeutic 
strategies are required. In this case any revascularization 
procedure (PCI or CABG) may be even more crucial and 
life saving.
The early stage of HM, when patients have only wall motion 
abnormalities and remodeling either has not occurred or is 
only minimal may reverse to normal (6) and thus may also be 
the “golden time” for revascularization of HM. With time, LV 
remodelling progressively increases and the amount of benefit 
of reverse remodeling may decline. So, early revascularization 
is of primary importance since the benefit is time sensitive 
and decreases with time and progression of remodeling (7). 
Bax et al. showed that after revascularization in stunned 
myocardium, contractile function improved significantly at 3 
months, without further improvement at 14 months. In HM, 
contractile function improved at 3 months, with a further 
improvement at 14 months (8).
In everyday practice, HM and stunned myocardium often 
coexist and contribute to progressive systolic dysfunction, 
remodeling, and the development of HF. Up to 60% of 
ischemic LV dysfunction has been attributed to dysfunctional 
but viable myocardium, and thus, there is a potentially good 
opportunity to improve outcome in many patients.
A previous study by Samady et al. revealed that lack 
of improvement of global LVEF after CABG is not 
associated with poorer outcome compared with that of 
patients with improved LVEF, presumably because effective 
revascularization of ischemic myocardium, even without 
improvement in ventricular function, protects from future 
infarction, ventricular arrhythmias and death postoperative. 
These findings indicate that in patients with LV dysfunction, 
methods for assessment of myocardial viability that focus 
on predicting improvement of ventricular function after 
revascularization may underestimate the potential for 
symptomatic and survival benefit achieved by CABG ().
Tarakji and co-workers in one of the largest cohorts of 
patients with advanced heart failure undergoing PET/FDG 
proved that among systolic heart failure patients referred for 
assessment of ischemia and viability with PET/FDG, early 
intervention [defined as any cardiac intervention (surgical 
or percutaneous) within the first 6 months of the PET/FDG 
study] may be associated with improved survival irrespective 
of the degree of viability (10). In the Global Registry of Acute 
Coronary Events (GRACE) heart failure reduced in-hospital 
and 6-month survival across all ACS subsets, including patients 
with normal markers of necrosis. In-hospital revascularization 
was associated with lower 6-month death rates (14.0% versus 
23.7%, p: 0.0001; adjusted hazard ratio, 0.5; 5% CI, 0.37 
- 0.68, p: 0.0001) (11)
Although PCI addresses a focal stenosis, whereas 
CABG treats an entire myocardial segment there are many 
limitations of the observational studies evaluating the effect of 
revascularization and the predictive value of viability testing in 
patients with ischemic LV dysfunction especially in patients at 
high perioperative risk. Imaging and coronary interventional 
techniques especially in the DES-era have improved over time, 
and earlier series may not accurately predict current outcomes. 
On the other hand a surgical operative mortality ranging from 
5% to 30% was observed in previous series depending on LV 
function and comorbidities (6).
PCI with DES implantation may be a feasible therapeutic 
alternative in patients with dialysis-dependent chronic renal 
failure and impaired LV systolic function at unacceptable 
high surgical risk.
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